Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients

por Chen Lin, Ke Chen, Jianjin Yu, Wei Feng, Weihong Fu, Fude Yang, Xiangyang Zhang, Dachun Chen
Publicado 2021

Schizophrenia and toxoplasmosis: association with catatonic symptoms

por Dmitry V. Romanov, Aleksey Iu. Brazhnikov, Denis S. Andreyuk, N. V. Zakharova, L. V. Bravve, Vasilisa A. Kovaleva, Evgeniya V. Abbazova, Dmitriy B. Goncharov, Irina V. Titova, Elvira A. Domonova, G. P. Kostyuk
Publicado 2020

Clinical Features of First-episode Psychoses During the COVID-19 Pandemic

por Vladimir A. Zyablov, Mikhail A. Gusev, Vasilyi S. Chizhikov
Publicado 2021

Affective temperaments of Lebanese patients with schizophrenia: comparison by gender and severity of psychosis

por Joseph E. Dib, Ilige Nehme, Chadia Haddad, Jocelyne Azar, Souheil Hallit, Sahar Obeid
Publicado 2021

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study

por Zhang H, Li H, Liu Y, Wu C, Wu Q, Nuamah I, Shi J, Xie S, Wang G, Gopal S
Publicado 2016

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

por Zhao JP, Li LH, Shi JG, Li Y, Xu XF, Li KQ, Zhang LL, Cai SL, Feng Y, Zhuo JM, Liu WH, Lu HF
Publicado 2017

Association study of the excitatory amino acid transporter 2 (EAAT2) and glycine transporter 1 (GlyT1) gene polymorphism with schizophrenia in a Polish population

por Merk W, Kucia K, Mędrala T, Kowalczyk M, Owczarek A, Kowalski J
Publicado 2019